Human Oocyte Cytoplasmic Maturation Optimization Solution

A technology of oocyte and cytoplasm, which is applied in the field of reproductive medicine engineering, can solve the problems of discarding and no use value, and achieve the effect of increasing the rate of high-quality embryos, promoting the maturation of oocyte nucleus and cytoplasm, and improving the developmental potential

Active Publication Date: 2020-01-07
江苏瑞辅达医疗器械有限公司
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The immature eggs collected are routinely considered to be of no use value and are directly discarded

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] The composition of human oocyte cytoplasm maturation optimization solution of the present invention is as follows:

[0018] 80%TCM199(V / V)+0.0022g / ml sodium pyruvate+0.075IU / ml FSH+0.5IU / ml HCG+0.8μg / ml estrogen+20%(V / V) human autologous serum+0.0060g / 100ml double antibody + 10μM melatonin.

[0019] in:

[0020] 1. Basic culture medium: TCM199‐‐‐100ml, batch number M4530, low sugar, no HEPEAS, company Sigma;

[0021] 2. Double antibody: use PENICILING (penicillin) and STREPTOMYCIN SULFATE (streptomycin), batch numbers are: LOT17H1214; LOT58H0442, company SIGMA;

[0022] 3. Sodium pyruvate: choose PYRUVIC ACID SODIUM (a‐ketopropionic acid), P‐2256, 25mg, batch number: LOT19H0645, company SIGMA;

[0023] 4. Estrogen: β‐ESTRADIOL (17β‐Estradiol) (estrogen), E‐2758, 250mg, batch number: 052K13705, company SIGMA;

[0024] 5. FSH / HCG: FSH-follicle-stimulating hormone, HCG-human chorionic gonadotropin; use Gonal-F / Profasi produced in Switzerland, Swithland;

[0025] 6. S...

example 1

[0062] In this case, a total of 88 oocytes were collected, 67 of which were mature, with a maturity rate of 76.1%, 51 of which were fertilized, with a fertilization rate of about 76.1%, 49 cleavage cells, with a cleavage rate of about 96.1%, and 12 blastocysts, with a blastocyst rate of 24.5% %, high-quality blastocyst 1, high-quality blastocyst rate 2%, blastocyst rate and high-quality blastocyst rate were significantly lower than Example 1, the former (blastocyst rate) was statistically significant (P<0.05) and the latter (high-quality Blastocyst rate) showed extremely significant statistical significance (P<0.01).

[0063] The invention discloses a liquid for optimizing human oocyte cytoplasmic maturation. The present invention is developed on the basis of low-sugar TCM199 tissue culture fluid combined with patient's autologous serum by adding some important hormones, energy substances and high-efficiency antioxidant melatonin. The present invention develops a culture medi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses mature optimized human oocyte cytoplasm fluid. The invention develops the mature optimized human oocyte cytoplasm fluid by adding some important hormones, energy substances and efficient antioxidant melatonin on the basis of low-sugar TCM199 tissue culture solution and patient autoserum. The invention develops a culture solution which is suitable for mature optimization of the oocyte cytoplasm in IVF-ET period and also is suitable for reutilization after in vitro maturity of the immature oocyte in the period. The mature optimized human oocyte cytoplasm fluid is capable of improving the maturity degree of the cytoplasm of the matured oocyte. A clinical result proves that the high-quality embryo rate of the oocyte is greatly increased, the development potential of the immature oocyte is increased and some immature oocytes in the IVF-ET period have a reutilization value.

Description

technical field [0001] The invention relates to a liquid for optimizing human oocyte cytoplasm maturation, which belongs to the field of reproductive medicine engineering. Background technique [0002] In vitro fertilization-embryo transfer (in vitro fertilization-embryo transfer, IVF-ET) patients can develop and grow multiple follicles on the ovaries after controlled ovulation stimulation. These eggs interact with sperm for in vitro fertilization. Why do eggs have to be cultured in vitro for a period of time after egg retrieval? Because, under normal circumstances, the nuclei of most of these eggs after egg retrieval are mature, marked by the first polar body discharged, but the cytoplasm is not mature enough, so it must be cultured in a specific culture medium It takes a period of time to promote the maturation of egg cytoplasm, and the immaturity of egg cytoplasm greatly reduces the fertilization rate of eggs, the rate of embryo formation and the rate of high-quality em...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N5/075
CPCC12N5/0609C12N2500/30C12N2501/31C12N2501/392C12N2501/825C12N2517/10
Inventor 章志国曹云霞魏兆莲周平陈蓓丽邹薇薇郝燕纪冬梅高明谢芬芬
Owner 江苏瑞辅达医疗器械有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap